Cargando…
Allergic reactions to the Ad26.COV2.S vaccine in South Africa
BACKGROUND: The Janssen-Ad26.COV2.S vaccine is authorized for use in several countries, with more than 30 million doses administered. Mild and severe allergic adverse events following immunization (AEFI) have been reported. OBJECTIVE: We sought to detail allergic reactions reported during the Sisonk...
Autores principales: | Peter, Jonny, Day, Cascia, Takuva, Simbarashe, Takalani, Azwidihwi, Engelbrecht, Imke, Garrett, Nigel, Goga, Ameena, Louw, Vernon, Opie, Jessica, Jacobson, Barry, Sanne, Ian, Gail-Bekker, Linda, Gray, Glenda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509997/ https://www.ncbi.nlm.nih.gov/pubmed/37780073 http://dx.doi.org/10.1016/j.jacig.2021.12.002 |
Ejemplares similares
-
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
por: Takuva, Simbarashe, et al.
Publicado: (2021) -
Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study)
por: Jacobson, Barry Frank, et al.
Publicado: (2023) -
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial
por: Takuva, Simbarashe, et al.
Publicado: (2022) -
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study
por: Bekker, Linda-Gail, et al.
Publicado: (2022) -
Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa
por: Goga, Ameena, et al.
Publicado: (2022)